Related Experiment Videos
In vivo interaction between steroidal alkylating agents and oestrogen receptors in rabbit uteri
Abstract:
The binding of steroidal alkylating agents to specific tissue component is necessary for the selective distribution of these compounds to their target tissues. The in vivo interaction of Estracyt or NSC-112259 with oestrogen receptors may play an important role in their action mechanism. Both Estracyt and NSC-112259 which were administered in vivo, gradually reduced the binding of [3H] oestradiol to cytoplasmic oestrogen receptor in rabbit uteri. From this, it was suggested that a negligible amount of oestradiol was released from these compounds and that the oestradiol moiety was useful as a carrier for the nitrogen mustard moiety. And it appeared that the synthesis of a new receptor protein was inhibited by the nitrogen mustard moiety, thereby causing a decrease in the cytoplasmic oestrogen receptor level.
Insights
Estracyt and NSC-112259 reduce estrogen receptor binding in rabbits. The estrogen component acts as a carrier for the nitrogen mustard, inhibiting new receptor synthesis.
Area of Science:
- Pharmacology
- Molecular Biology
- Endocrinology
Background:
- Steroidal alkylating agents require specific tissue binding for targeted delivery.
- Estracyt (NSC-112259) is a steroidal alkylating agent whose mechanism may involve estrogen receptors.
Purpose of the Study:
- To investigate the in vivo interaction of Estracyt/NSC-112259 with estrogen receptors.
- To elucidate the role of the estrogen moiety and nitrogen mustard moiety in the action of Estracyt.
Main Methods:
- In vivo administration of Estracyt/NSC-112259 to rabbits.
- Measurement of [3H] estradiol binding to cytoplasmic estrogen receptors in rabbit uteri.
Main Results:
- Estracyt and NSC-112259 administration progressively decreased [3H] estradiol binding to cytoplasmic estrogen receptors.
- Evidence suggests minimal estradiol release, indicating the estradiol moiety functions as a carrier.
- The nitrogen mustard moiety appears to inhibit the synthesis of new estrogen receptor proteins.
Conclusions:
- The estrogen moiety of Estracyt serves as a carrier for the active nitrogen mustard component.
- The therapeutic effect of Estracyt may be mediated by the inhibition of estrogen receptor synthesis by the nitrogen mustard moiety.